Injecting the GLP-1 receptor agonist exendin-4 into the dorsolateral septum brain region reduced alcohol self-administration and relapse in male high-drinking rats without affecting food intake or body weight.
Reduced relapse to drinkingIntra-dLS exendin-4 reduced reacquisition of alcohol self-administration in high-drinking male rats, identifying a specific brain region mediating GLP-1's anti-addiction effects
What the researchers found
Direct injection of exendin-4 (25 ng) into the dorsolateral septum (dLS) significantly reduced ethanol operant self-administration in male high-responder rats but had no effect in male low responders or females. In relapse tests, intra-dLS exendin-4 reduced reacquisition of ethanol self-administration — a model of relapse to drinking after abstinence — but did not affect prime + context-induced reinstatement of ethanol seeking, a model of cue/context-triggered relapse.
Importantly, the alcohol reduction occurred without sustained changes in 24-hour food intake or body weight, indicating the effect was specific to reward processing rather than general appetite suppression. Retrograde tracing confirmed that the dLS receives direct input from GLP-1-producing neurons in the nucleus tractus solitarius (NTS), establishing an anatomical basis for this signaling pathway.
Why it matters
Alcohol use disorder affects over 400 million people globally and has few effective treatments. GLP-1 receptor agonists are generating enormous clinical interest for addiction, but understanding which brain circuits they act through is essential for developing targeted therapies. This study identifies the dorsolateral septum as a specific brain region mediating GLP-1's effects on alcohol consumption and identifies the NTS-to-dLS pathway as a neural circuit that could be targeted by future treatments.
How the study worked
Long Evans rats were given intermittent access to 20% ethanol solution before being trained in operant self-administration (lever-pressing for alcohol). On test days, rats received microinjections of exendin-4 (5 ng or 25 ng) or vehicle directly into the dorsolateral septum. For relapse testing, operant responding was first extinguished, then two relapse models were tested: reacquisition (alcohol made available again) and prime + context-induced reinstatement (alcohol priming dose plus environmental cues). Retrograde tracing mapped neural inputs to the dLS from GLP-1-expressing neurons.
What this study cannot tell us
This is an animal study using direct brain injection, which is not a clinically practical delivery method. The sex-specific effects (working in males only) may not translate directly to humans, but they highlight important biological differences that need to be understood. The study used a single GLP-1 agonist (exendin-4) and may not reflect the pharmacology of other GLP-1 drugs like semaglutide or liraglutide. The distinction between high and low responders was based on the specific cohort and may not generalize across rat strains.
How to read the evidence
This is a well-designed preclinical study using established behavioral models of addiction and anatomical tracing to support the findings. The evidence is strong for the animal model but cannot be directly applied to human clinical practice. It provides mechanistic insight that supports the rationale for clinical trials of GLP-1 agonists in alcohol use disorder.
When this study was published
Published in 2025, this is a very recent study at the forefront of research into GLP-1 peptide signaling in addiction neuroscience.
The bigger picture
There is growing clinical interest in repurposing GLP-1 receptor agonists like semaglutide for alcohol use disorder, with observational data and early trials suggesting benefit. This study provides critical mechanistic insight by mapping the specific brain circuitry involved. The finding that GLP-1 reduces relapse through reacquisition but not cue-induced reinstatement suggests that different relapse triggers involve different neural mechanisms — important information for designing combination therapies that address multiple relapse pathways.
Questions still open
- Do systemically administered GLP-1 drugs like semaglutide reduce alcohol consumption at least partly through this dorsolateral septum pathway?
- Why did female rats not respond to intra-dLS GLP-1 stimulation, and what does this mean for sex differences in GLP-1 treatment of alcohol use disorder?
- Could targeting the NTS-to-dLS circuit specifically allow for more precise treatments for alcohol addiction without the metabolic side effects of systemic GLP-1 therapy?
Common questions
Could GLP-1 drugs like Ozempic help people with alcohol problems?
What is the dorsolateral septum and why does it matter for addiction?
Read the original research
Effects of glucagon-like peptide 1 receptor signaling in the dorsolateral septum on ethanol operant self-administration and relapse behaviors.
Neuropharmacology, 279, 110640
Citation
Xiao, Yuqing; Yap, Jo Ann; Ong, Zhi Yi. (2025). Effects of glucagon-like peptide 1 receptor signaling in the dorsolateral septum on ethanol operant self-administration and relapse behaviors.. Neuropharmacology, 279, 110640. https://doi.org/10.1016/j.neuropharm.2025.110640